Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Debt (2016 - 2018)

Anaptysbio (ANAB) has disclosed Total Debt for 3 consecutive years, with $625000.0 as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Total Debt fell 91.73% year-over-year to $625000.0, compared with a TTM value of $625000.0 through Dec 2018, down 91.73%, and an annual FY2018 reading of $625000.0, down 91.73% over the prior year.
  • Total Debt was $625000.0 for Q4 2018 at Anaptysbio, down from $2.4 million in the prior quarter.
  • Across five years, Total Debt topped out at $13.8 million in Q4 2016 and bottomed at $625000.0 in Q4 2018.
  • Average Total Debt over 3 years is $7.5 million, with a median of $7.6 million recorded in 2017.
  • The sharpest move saw Total Debt tumbled 45.3% in 2017, then plummeted 91.73% in 2018.
  • Year by year, Total Debt stood at $13.8 million in 2016, then crashed by 45.3% to $7.6 million in 2017, then tumbled by 91.73% to $625000.0 in 2018.
  • Business Quant data shows Total Debt for ANAB at $625000.0 in Q4 2018, $2.4 million in Q3 2018, and $4.1 million in Q2 2018.